LitAlert ~~ GeneLit.com

    • Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.
    • Voutsadakis IA, Stravodimou A.
    • Anticancer Res. 2023 Mar;43(3):967-981. doi: 10.21873/anticanres.16241.

    • A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
    • Malhotra MK, Pahuja S, Kiesel BF, Appleman LJ, Ding F, Lin Y, Tawbi HA, Stoller RG, Lee JJ, Belani CP, Chen AP, Giranda VL, Shepherd SP, Emens LA, Ivy SP, Chu E, Beumer JH, Puhalla S.
    • Breast Cancer Res Treat. 2023 Feb 28. doi: 10.1007/s10549-023-06889-0. Epub ahead of print.

    Related:

    •• Identifier: NCT01281150: Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Feb 28.)

    • Characterization of BRCA Deficiency in Ovarian Cancer.
    • Barbero G, Zuntini R, Magini P, Desiderio L, Bonaguro M, Perrone AM, Rubino D, Grippa M, De Leo A, Ceccarelli C, Godino L, Miccoli S, Ferrari S, Santini D, De Iaco P, Zamagni C, Innella G, Turchetti D.
    • Cancers (Basel). 2023 Feb 28;15(5):1530. doi: 10.3390/cancers15051530.

    • Somatic and Germline Aberrations in Homologous Recombination Repair Genes in Chinese Prostate Cancer Patients.
    • Liu YX, Jin B, Shen C, Gao XS, Qi X, Ma M, Li HZ, Hao H, Tang Q, Yang K, Mi Y, Guan J, He Z, Haixia L, Yu W.
    • Front Oncol. 2023 Feb 28;13:1086517. doi: 10.3389/fonc.2023.1086517.

    • A Review of Treatments Targeting DNA-Repair Gene Defects in Metastatic Castration Resistant Prostate Cancer.
    • Maslov DV, Sember Q, Cham J, Bhangoo M.
    • Front Oncol. 2023 Feb 28;13:1150777. doi: 10.3389/fonc.2023.1150777.

    • Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    • Tang Q, Zuo W, Wan C, Xiong S, Xu C, Yuan C, Sun Q, Zhou L, Li X.
    • Front Immunol. 2023 Feb 3;13:1097730. doi: 10.3389/fimmu.2022.1097730.